Weight-Loss Drugs Are Changing Cardiovascular Care
Drugs like GLP-1 Receptor Agonists may become important treatment options independent of weight loss or glycemic control.
Weight-loss drugs like Wegovy and Ozempic have exploded in popularity in recent years, finally offering an effective pharmaceutical option for treating conditions like type 2 diabetes and chronic obesity. As we learn more about the effects these medications have on the body, researchers are finding evidence that these drugs provide significant cardiovascular benefits that can’t be attributed to weight loss alone. And that may open the door to their use as a front-line therapy to treat cardiovascular disease (CVD).
Taking Obesity Seriously
Obesity has a drastic impact on the body, increasing the risk of type 2 diabetes, high blood pressure, abnormal cholesterol levels, kidney disease, sleep apnea, and certain cancers. Its effects on the cardiovascular system are particularly significant: people with obesity are more likely to develop coronary artery disease, heart attack, stroke, and heart failure, and excess body fat can contribute to chronic inflammation and other changes that place additional stress on the heart and blood vessels.
Yet obesity has historically been difficult to treat. Diet and exercise remain important components of a healthy lifestyle, but biological mechanisms can make substantial, sustained weight loss difficult for many people. At the same time, people with obesity have often faced considerable stigma—including the misconception that obesity simply reflects a lack of willpower. Or even a moral failing. But obesity is now increasingly understood as a complex chronic disease influenced by factors like genetics, metabolism, environment, and behavior.
These new medications have helped reframe obesity as a treatable disease, and in doing so offer a potential path to better health for millions worldwide.
A New Approach to Metabolic Disease
This new generation of weight-loss drugs mimic a natural gut hormone to control blood sugar, slow digestion, and reduce appetite. The hormone Glucagon-like peptide-1 (GLP-1) helps stimulate insulin release when blood glucose is elevated, suppresses glucagon, slows stomach emptying, and influences areas of the brain involved in hunger and satiety. Drugs called GLP-1 receptor agonists mimic the naturally occurring hormone to reproduce these effects.
Originally prescribed to help control diabetes, these medications have become popular as mainstream weight-loss drugs like Ozempic and WeGovy. At higher doses, some of these medications can produce average weight reductions approaching those of bariatric surgery.
Other medications combine GLP-1 drugs with others that mimic the hormone glucose-dependent insulinotropic polypeptide (GIP) to increase the effects. More hormones and combinations are currently being explored, with potential for even greater results.
While these drugs often produce unwanted side effects, including nausea, vomiting, diarrhea, and constipation, their efficacy in reducing body weight has transformed the medical landscape. For the first time, clinicians have nonsurgical medications that can produce substantial, sustained weight loss in many patients.
But as data for cardiovascular safety accumulated, researchers began seeing evidence that these drugs had clear cardiovascular benefits, including a reduction in heart attacks, strokes, and cardiovascular-related deaths.
The First Signs of Cardiovascular Protection
The LEADER trial, published in 2016, enrolled 9,340 people with type 2 diabetes and high cardiovascular risk. Participants were randomly assigned to receive liraglutide or a placebo in addition to standard treatment.
The study evaluated a composite cardiovascular endpoint consisting of cardiovascular death, nonfatal heart attack, or nonfatal stroke—commonly known as three-point major adverse cardiovascular events, or MACE.
MACE occurred in 13.0% of participants receiving liraglutide compared with 14.9% receiving placebo, representing a 13% relative reduction in risk, with cardiovascular death 22% lower among participants receiving liraglutide.
The FDA subsequently approved a CV-risk-reduction indication for adults with type 2 diabetes and established cardiovascular disease.
Researchers have examined the results to determine what drove this reduction, looking at factors like body weight, blood glucose, blood pressure, cholesterol, and kidney measures to explain liraglutide's cardiovascular effect. Changes in body weight appeared to explain only a portion of the benefit.
Additional trials like SUSTAIN-6 and REWIND provided further evidence of substantial reductions in cardiovascular events that could not be fully attributed to weight loss or glucose control.
Looking Beyond Injectables
The SOUL trial, published in 2025, asked whether the cardiovascular benefits associated with injectable semaglutide would extend to an oral formulation. One of the challenges with these medications is the general reluctance to use injectables, so oral medications are an important option for wider adoption.
The study enrolled 9,650 people with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both. The trial used the dosage and titration used for the treatment of type 2 diabetes at the time of the trial, rather than the levels commonly prescribed for weight loss.
Participants receiving oral semaglutide experienced approximately a 14% relative reduction in MACE compared with placebo. The cardiovascular benefit occurred without the degree of weight loss typically seen with high-dose semaglutide used specifically for obesity, again suggesting that major weight reduction is not a prerequisite for cardiovascular benefit.
While not dismissing the clear benefit of weight loss on cardiovascular outcomes, these trials strengthen the idea that these medications may protect the cardiovascular system through multiple pathways, with weight loss representing only one component.
Benefits for a Broader Population
Earlier cardiovascular trials largely involved people with type 2 diabetes, so improvements in blood glucose could potentially explain at least some of the cardiovascular protection.
In the SELECT trial, researchers asked whether adding semaglutide to standard care would reduce the risk of major adverse cardiovascular events in patients with overweight or obesity and preexisting cardiovascular disease who did not have diabetes.
Published in 2023, SELECT enrolled 17,604 adults age 45 or older who had overweight or obesity and established cardiovascular disease but did not have diabetes. The study showed a 20% reduction in major adverse cardiac events vs placebo.
The study established that semaglutide could reduce cardiovascular events in people with overweight or obesity, even in the absence of diabetes. The FDA approved this indication in 2024.
One remarkable aspect of the results is that these cardiovascular benefits appear as early as three months, meaning they precede significant weight loss. Data also demonstrate reductions in all-cause mortality and heart failure events, as well as improvements in kidney and glycemic indicators, in this early period. This timeline suggests that these changes were driven in part by another mechanism associated with semaglutide.
Potential mechanisms being investigated include reductions in systemic inflammation, improvements in endothelial function and blood pressure, changes in lipid metabolism, effects on atherosclerotic plaque, and improvements in kidney and metabolic function.
Additional trials have established a relationship with these medications and risk reduction associated with heart failure, peripheral artery disease (PAD), and chronic kidney disease.
A Shifting Landscape
Researchers still need to determine exactly which mechanisms are responsible for cardiovascular protection and how much of the benefit is attributable to weight loss versus direct and indirect pharmacologic effects.
Ongoing cardiovascular outcomes trials should provide additional answers, including whether these medications can prevent first cardiovascular events in people who have risk factors but no established cardiovascular disease.
But with mounting evidence of cardiovascular benefits, drug manufacturers are racing to develop new therapies with even greater efficacy; dozens of similar drugs are currently being evaluated.
While these finds have the potential to reshape how we treat cardiovascular disease, this new path faces the same challenges to making these medications widely available and practical for patients for weight loss.
These medications can be expensive, and insurance coverage remains inconsistent. Coverage for diabetes, obesity, and cardiovascular indications can differ substantially, even when the same medication is involved. Patients may also encounter prior authorization requirements, shortages, and other barriers to treatment.
The expanding role these medications play in treating or preventing CVD may help drive insurance providers to rethink their approach. And the potential increase in the number of available drugs may help drive down cost. But it seems clear that these drugs will play a significant part in how we treat CVD in the future.
Related